Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 03, 2022

First-Line Pembrolizumab, Trastuzumab, and Doublet Chemotherapy for Advanced HER2-Positive Gastric Cancer

Nature Communications


Additional Info

Disclosure statements are available on the authors' profiles:

Nature Communications
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
Nat Commun 2022 Oct 12;13(1)6002, CK Lee, SY Rha, HS Kim, M Jung, B Kang, J Che, WS Kwon, S Park, WK Bae, DH Koo, SJ Shin, H Kim, HC Jeung, DY Zang, SK Lee, CM Nam, HC Chung

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading